drugset / Trial / NCT00878423
Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors
NaSingle-groupOpen-labelBasic science
Summary
AT13387/0001 is a dose-finding study of an experimental anticancer agent. In accordance with the protocol increasing doses of AT13387 are given to patients with advanced cancer who do not have alternative treatment options. The preferred dose of AT13387 will be identified according to the side effects experienced at different dose levels.
Timeline
- Start
- 2008-05
- Primary completion
- 2013-05
- Completion
- 2014-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Onalespib | Small molecule | 10 mg/m2 | Intravenous |
| Subject | Onalespib | Small molecule | 150 mg/m2 | Intravenous |